Compare LGIH & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | CMPS |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2013 | 2020 |
| Metric | LGIH | CMPS |
|---|---|---|
| Price | $53.27 | $11.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $75.90 | $25.38 |
| AVG Volume (30 Days) | 380.2K | ★ 4.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $17.94 | N/A |
| P/E Ratio | $562.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $2.25 |
| 52 Week High | $69.42 | $14.76 |
| Indicator | LGIH | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 66.01 | 50.85 |
| Support Level | $41.41 | $5.37 |
| Resistance Level | $55.13 | $14.76 |
| Average True Range (ATR) | 2.39 | 1.02 |
| MACD | 0.55 | -0.21 |
| Stochastic Oscillator | 93.91 | 24.08 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.